Cytodyn Inc. (CYDY) Stock Price & Analysis
Cytodyn Inc. (CYDY) fell 0.34% to USD 0.3 as of June 10, 2026 at 05:09 UTC, according to Nexqual real-time market data.
CYDY last closed at USD 0.3; the session ranged USD 0.29–0.3 on volume of 789,942 shares. Market capitalization is $404.07M, with a 52-week range of USD 0.21–0.4 (OQB). Source: Nexqual, June 10, 2026 at 05:09 UTC.
Key Statistics (as of June 10, 2026 at 05:09 UTC)
| Price | USD 0.3 |
|---|---|
| Change | ▼ 0.34% (down) |
| Previous Close | USD 0.3 |
| Open | USD 0.3 |
| Day Range | USD 0.29 – 0.3 |
| 52-Week Range | USD 0.21 – 0.4 |
| Volume | 789,942 shares |
| Market Cap | $404.07M |
| Exchange | OQB |
Technical Analysis (CYDY)
Nexqual's technical model rates CYDY "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:09 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.59 (neutral) |
| vs SMA50 | Below (USD 0.32) |
| MACD | -0.01 (negative) |
Analyst Ratings (CYDY)
Wall Street analysts rate CYDY "None", per Nexqual as of June 10, 2026 at 05:09 UTC.
| Consensus Rating | None |
|---|
Earnings (CYDY)
| Next Earnings Date | 2026-04-08 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2021-02-28 | USD -0.05 vs est -0.05 ▲ beat |
| 2020-11-30 | USD -0.06 vs est -0.05 ▼ miss |
| 2020-08-31 | USD -0.06 vs est -0.06 ▲ beat |
| 2020-05-31 | USD -0.07 vs est -0.05 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Financials & Fundamentals (CYDY)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.37 |
| Total Cash | $15.65M |
| Total Debt | $28.82M |
| Free Cash Flow | $-4.85M |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Financial Health Score (CYDY)
Nexqual rates Cytodyn Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:09 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $16M cash vs $29M debt |
| Cash Flow | Weak — Operating cash flow -$18M |
| Efficiency | Mixed — No data |
Ownership (CYDY)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +0.02% |
| Shares Outstanding | 1.37B |
| Float | 1.37B |
Source: Nexqual, June 10, 2026 at 05:09 UTC.
Leadership (CYDY)
Cytodyn Inc. is led by Jacob P. Lalezari (age 65), Chief Executive Officer, per Nexqual as of June 10, 2026 at 05:09 UTC.
| Chief Executive Officer | Jacob P. Lalezari (age 65) |
|---|---|
| Vice President of Operations | Bernie Cunningham P.M.P. |
From Cytodyn Inc.'s Latest SEC 10-K Filing (filed 2025-07-25)
Key Strengths & Strategy (as disclosed to the SEC)
- CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications.
- It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19.
- The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RLFTF | MindMaze Therapeutics Holding S | USD 0.42 | ▼ 12.92% |
| VXRT | Vaxart, Inc. | USD 0.58 | ▼ 6.45% |
| CODX | Co-Diagnostics, Inc. | USD 4.5 | ▼ 20.07% |
| IBIO | iBio, Inc. | USD 1.7 | ▼ 6.59% |
| SRNE | Sorrento Therapeutics, Inc. | USD 0 | ▲ 200% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:09 UTC. This page is informational and not investment advice.